Glen Carter — Biotech Strategy Consultant

About Me

I'm a chemist turned strategy consultant, working mostly with biotech startups. My PhD at the École Normale Supérieure went deep into the physics of reading information out of DNA — but the longer I spent at the bench, the more a different question pulled at me: not just whether a piece of science is good, but whether it's worth building, and how it ever leaves the lab.

So I went and learned the other half. An executive MBA, a deep-tech venture I founded and ran, an organisational transformation inside a global pharma, and now independent strategy consulting — helping biotech founders and pharma teams decide what's worth building and how to bring it to market. I read a term sheet and a thesis with equal ease.

What I really do is translate: between the lab bench and the strategy deck, between what is scientifically true and what is commercially smart. And I build — usually several things at once: an AI platform for biotech investors, a private on-device dictation app for Mac, small tools for whatever problem is in front of me. Based in Paris and originally from Dublin, I'm most useful where biology, software and capital meet.

Strategic Expertise

Biotech Market Analysis

Judging which emerging life-science technologies are genuinely worth backing.

R&D Portfolio Strategy

Where a pharmaceutical research budget should go — and the analysis behind it.

Operational Excellence

QMS and regulatory pathways that move products to market faster.

Experience

Degrees, roles and ventures on a single timeline — overlapping bars show what ran in parallel. Select any row to read more.

Education Full-time Part-time Entrepreneurial Intermittent

Education 2012 – 2016

BSc, Chemical & Pharmaceutical Sciences

Dublin City University

Four-year honours degree in chemical and pharmaceutical sciences, with a research thesis. 2nd Class Honours.

Education 2017 – 2018

MSc, Chemistry & Life Sciences

École Normale Supérieure

Research masters at the interface of chemistry and biology. Graduated Mention Très Bien — 1st Class Honours.

Full-time 2018 – 2019

Regulatory Affairs Specialist & Scientific Advisor

Lallemand

Led product registrations across 9 South-East Asian countries; advised regulatory affairs officers on compliance requirements.

Part-time 2018 – 2021

Chemist & Formulations Consultant

Lilly's Eco Clean

Recurring one-to-two-month contracts supporting formulation development and EU CLP regulatory classifications — run in parallel with the MSc, PhD and BforCure work.

Full-time 2019 – 2021

Chemistry R&D Engineer

BforCure

Co-developed qPCR kits for COVID-19 and respiratory viruses. Oversaw design, installation and regulatory compliance of the chemistry lab; supervised 2 interns.

Education 2020 – 2023

MBA, Science Management

Collège des Ingénieurs

Executive MBA in Science Management, taken within the Collège des Ingénieurs fellowship — a competitive three-year programme (under 5% admission) that combined the doctorate with rotational placements at leading European firms.

Education 2020 – 2023

Doctoral Researcher

École Normale Supérieure

"Innovative Strategies for DNA Analysis using Supramolecular Assemblies and qPCR Multiplexing." Developed high-content PCR (hcPCR) — a multiplexing method that resolves multiple targets per optical channel by deconvolving each probe's temperature–fluorescence signature — and discovered light-based detection of single-point mutations in short DNA sequences.

Part-time 2022 – 2023

VC Scout

G. Ventures

Investment scout and content/community manager — deal sourcing and community building.

Part-time 2022 – Present

VP, Alumni Association

Collège des Ingénieurs

Vice-President of the Collège des Ingénieurs alumni association — building the French alumni community through networking events and TED-talk projects.

Entrepreneurial 2023 – 2024

Founder & CEO

Micromagnetix Biophysics

Founded a deep-tech biotech venture out of PSL Research University in partnership with a multinational pharmaceutical company. Led company structure, negotiation strategy and market positioning; concluded the venture in 2024 after evaluating commercial viability against alternative paths into strategy consulting.

Entrepreneurial 2023 – Present

Founder · Catalyst Ventures

Catalyst Ventures

Founded and built an AI-powered biotech investment-intelligence platform covering 350+ US and EU tickers — parsing SEC filings, tracking FDA/EMA catalysts and generating sentiment scores and daily executive summaries. Also leads the associated investment club.

Full-time Jul 2023 – Feb 2024

Organisational Capabilities Strategist

Sanofi Digital

Project-managed the organisational transformation of 2,400 employees, lifting productivity ~10%. Future-proofed organisational health and improved decision-making structures — a rotational placement within the Collège des Ingénieurs fellowship.

Entrepreneurial 2025 – Present

Builder · Gist

Gist

Designed and shipped Gist — a native macOS app that turns speech into polished email, prompts and notes in any app, with transcription and AI running 100% on-device (Gemma via Apple MLX): no cloud, no account. Also built an on-device speaking coach that trains clearer, more confident delivery from your own dictations. Stack: SwiftUI, MLX.

Part-time Feb 2024 – Present

Independent Strategy Consultant

Carter Consulting (Auto-Entrepreneur)

Independent strategy consulting for pharma and biotech clients across Switzerland, France and Germany. Led the market positioning and portfolio analysis behind a multi-billion-euro decision on a large European pharma's obesity-drug assets, and developed R&D portfolio, go-to-market and optimisation strategies for top pharmaceutical clients. Acting QMS lead for a large pharmaceutical client, with strategic frameworks delivering ~20% operational efficiency gains.

Entrepreneurial Apr – Jun 2024

Founder in Residence

Entrepreneur First

Selected for a competitive 3-month founder programme. Explored personalised diagnostics, electrochemical biosensors and DNA computing before returning focus to Micromagnetix.

Doctoral Research

My PhD at the École Normale Supérieure (PSL University) — Innovative Strategies for DNA Analysis using Supramolecular Assemblies and qPCR Multiplexing — built new ways to read more information out of a DNA test. I've rebuilt three of its core ideas as interactive models you can explore.

Chapter 3

Programmable DNA Self-Assembly

Molecular beacons that capture a short target and chain themselves into a self-assembling supramolecular network.

Explore the model Chapter 3

Molecular Beacons & SNP Detection

A second melting fingerprint, T_m*, that pulls single-base mutations apart on a two-dimensional map.

Explore the model Chapter 2

hcPCR — One Channel, Many Targets

Reading several targets from a single optical channel by their fluorescence–temperature waveforms.

Explore the model

Open the interactive thesis

Projects

Featured Web App

Catalyst Ventures

AI-Powered Biotech Investment Intelligence

An AI-powered biotech investment intelligence platform covering 350+ US and EU tickers. It uses Python and the Google Gemini API to parse SEC filings, track FDA/EMA catalysts, and generate sentiment scores and daily executive summaries for investors.

Real-time sentiment analysis
Automated SEC filing parsing
FDA / EMA catalyst tracking

Python Google Gemini API Data Visualization Vanilla JS

Visit Platform

Catalyst Ventures — institutional-grade biotech investment intelligence dashboard

On-Device AI · macOS

Gist

Private On-Device AI Dictation for macOS

A native macOS app that turns your voice into polished email, prompts, messages and notes in any app — with transcription and AI running 100% on your Mac. No cloud, no account. It also includes an on-device speaking coach that helps you deliver clearer, more confident dictation, with every word staying private to your machine.

100% on-device (Gemma via Apple MLX)
Works in any app — no cloud, no account
Built-in on-device speaking coach

SwiftUI Apple MLX On-Device AI macOS

View Product

Writing & Insights

Essays and analysis on biotech strategy, molecular diagnostics, AI and the business of science. A selection below — the full archive, with publications, lives on the articles page.

Analysis January 2026

Quantifying the Edge: Statistical Arbitrage in Clinical-Stage Biotech Events

An analysis of statistical-arbitrage approaches to clinical-stage biotech catalysts, published on Catalyst Ventures.

Read on Catalyst Ventures

Browse all articles & insights

Languages & Interests

Languages

Interests

Personalised Healthcare Longevity & Epigenetics Molecular Diagnostics Biotech Investing Building with AI Sailing Skiing Strength & Combat Sports

Let's Connect

I'm based in Paris and open to discussing opportunities in Strategy, Biotech, and Tech.

Book a Strategy Call

Email: [email protected]

Phone: +33 6 28 37 04 38